390 related articles for article (PubMed ID: 26945421)
21. Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response.
Onishi N; Li W; Newitt DC; Harnish RJ; Strand F; Nguyen AA; Arasu VA; Gibbs J; Jones EF; Wilmes LJ; Kornak J; Joe BN; Price ER; Ojeda-Fournier H; Eghtedari M; Zamora KW; Woodard S; Umphrey HR; Nelson MT; Church AL; Bolan PJ; Kuritza T; Ward K; Morley K; Wolverton D; Fountain K; Lopez Paniagua D; Hardesty L; Brandt KR; McDonald ES; Rosen M; Kontos D; Abe H; Sheth D; Crane E; Dillis C; Sheth P; Hovanessian-Larsen L; Bang DH; Porter B; Oh KY; Jafarian N; Tudorica LA; Niell B; Drukteinis J; Newell MS; Giurescu ME; Berman E; Lehman CD; Partridge SC; Fitzpatrick KA; Borders MH; Yang WT; Dogan B; Goudreau SH; Chenevert T; Yau C; DeMichele A; Berry DA; Esserman LJ; Hylton NM
Radiology; 2021 Nov; 301(2):295-308. PubMed ID: 34427465
[TBL] [Abstract][Full Text] [Related]
22. Magnetic resonance imaging evaluation of residual tumors in breast cancer after neoadjuvant chemotherapy: surgical implications.
Zhou J; Li G; Sheng F; Qiao P; Zhang H; Xing X
Acta Radiol; 2016 May; 57(5):529-37. PubMed ID: 26231950
[TBL] [Abstract][Full Text] [Related]
23. Predictive Clinicopathologic and Dynamic Contrast-Enhanced MRI Findings for Tumor Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Eom HJ; Cha JH; Choi WJ; Chae EY; Shin HJ; Kim HH
AJR Am J Roentgenol; 2017 Jun; 208(6):W225-W230. PubMed ID: 28350486
[TBL] [Abstract][Full Text] [Related]
24. Breast parenchymal signal enhancement ratio at preoperative magnetic resonance imaging: association with early recurrence in triple-negative breast cancer patients.
Park VY; Kim EK; Kim MJ; Yoon JH; Moon HJ
Acta Radiol; 2016 Jul; 57(7):802-8. PubMed ID: 26516288
[TBL] [Abstract][Full Text] [Related]
25. Computer-aided Diagnosis-generated Kinetic Features of Breast Cancer at Preoperative MR Imaging: Association with Disease-free Survival of Patients with Primary Operable Invasive Breast Cancer.
Kim JJ; Kim JY; Kang HJ; Shin JK; Kang T; Lee SW; Bae YT
Radiology; 2017 Jul; 284(1):45-54. PubMed ID: 28253106
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of response evaluation based on breast MRI after neoadjuvant treatment: a retrospective cohort study.
Bitencourt AGV; Pires BS; Calsavara VF; Negrão EMS; Souza JA; Graziano L; Guatelli CS; Makdissi FB; Sanches SM; Tavares MC; Osório CABT; De Brot M; Marques EF; Chojniak R
Eur Radiol; 2021 Dec; 31(12):9520-9528. PubMed ID: 34036420
[TBL] [Abstract][Full Text] [Related]
27. Ring Enhancement in Non-Neoplastic Breast Tissue on MRI During Neoadjuvant Chemotherapy for Breast Cancer: Incidence and Clinical Implications.
Oh J; Han BK; Ko EY; Ko ES; Choi JS; Kim H; Park YH; Kim JY
Acad Radiol; 2023 Dec; 30(12):2931-2939. PubMed ID: 37045651
[TBL] [Abstract][Full Text] [Related]
28. MRI background parenchymal enhancement, fibroglandular tissue, and mammographic breast density in patients with invasive lobular breast cancer on adjuvant endocrine hormonal treatment: associations with survival.
Lo Gullo R; Daimiel I; Rossi Saccarelli C; Bitencourt A; Sevilimedu V; Martinez DF; Jochelson MS; Morris EA; Reiner JS; Pinker K
Breast Cancer Res; 2020 Aug; 22(1):93. PubMed ID: 32819432
[TBL] [Abstract][Full Text] [Related]
29. Early assessment of breast cancer response to neoadjuvant chemotherapy by semi-quantitative analysis of high-temporal resolution DCE-MRI: preliminary results.
Abramson RG; Li X; Hoyt TL; Su PF; Arlinghaus LR; Wilson KJ; Abramson VG; Chakravarthy AB; Yankeelov TE
Magn Reson Imaging; 2013 Nov; 31(9):1457-64. PubMed ID: 23954320
[TBL] [Abstract][Full Text] [Related]
30. Accuracy of Contrast-Enhanced Ultrasound Compared With Magnetic Resonance Imaging in Assessing the Tumor Response After Neoadjuvant Chemotherapy for Breast Cancer.
Lee SC; Grant E; Sheth P; Garcia AA; Desai B; Ji L; Groshen S; Hwang D; Yamashita M; Hovanessian-Larsen L
J Ultrasound Med; 2017 May; 36(5):901-911. PubMed ID: 28150325
[TBL] [Abstract][Full Text] [Related]
31. Hypervascularity Predicts Complete Pathologic Response to Chemotherapy and Late Outcomes in Breast Cancer.
Bufi E; Belli P; Di Matteo M; Giuliani M; Tumino M; Rinaldi P; Nardone L; Franceschini G; Mulé A; Bonomo L
Clin Breast Cancer; 2016 Dec; 16(6):e193-e201. PubMed ID: 27431459
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant Chemotherapy and Surgery for Breast Cancer: Preoperative MRI Features Associated with Local Recurrence.
Shin SU; Cho N; Lee HB; Kim SY; Yi A; Kim SY; Lee SH; Chang JM; Moon WK
Radiology; 2018 Oct; 289(1):30-38. PubMed ID: 30040058
[TBL] [Abstract][Full Text] [Related]
33. Background parenchymal enhancement: behavior during neoadjuvant chemotherapy for breast cancer and relationship with a pathological complete response.
Teixeira SRC; de Camargo Júnior HSA; Cabello C
Radiol Bras; 2020; 53(2):95-104. PubMed ID: 32336824
[TBL] [Abstract][Full Text] [Related]
34. Dynamic contrast-enhanced breast magnetic resonance imaging for the prediction of early and late recurrences in breast cancer.
Choi EJ; Choi H; Choi SA; Youk JH
Medicine (Baltimore); 2016 Nov; 95(48):e5330. PubMed ID: 27902592
[TBL] [Abstract][Full Text] [Related]
35. Use of dynamic contrast-enhanced MR imaging to predict survival in patients with primary breast cancer undergoing neoadjuvant chemotherapy.
Li SP; Makris A; Beresford MJ; Taylor NJ; Ah-See ML; Stirling JJ; d'Arcy JA; Collins DJ; Kozarski R; Padhani AR
Radiology; 2011 Jul; 260(1):68-78. PubMed ID: 21502383
[TBL] [Abstract][Full Text] [Related]
36. Bilateral asymmetry of quantitative parenchymal kinetics at ultrafast DCE-MRI predict response to neoadjuvant chemotherapy in patients with HER2+ breast cancer.
Ren Z; Pineda FD; Howard FM; Fan X; Nanda R; Abe H; Kulkarni K; Karczmar GS
Magn Reson Imaging; 2023 Dec; 104():9-15. PubMed ID: 37611646
[TBL] [Abstract][Full Text] [Related]
37. Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging.
Iotti V; Ravaioli S; Vacondio R; Coriani C; Caffarri S; Sghedoni R; Nitrosi A; Ragazzi M; Gasparini E; Masini C; Bisagni G; Falco G; Ferrari G; Braglia L; Del Prato A; Malavolti I; Ginocchi V; Pattacini P
Breast Cancer Res; 2017 Sep; 19(1):106. PubMed ID: 28893303
[TBL] [Abstract][Full Text] [Related]
38. Repeated surgeries in invasive lobular breast cancer with preoperative MRI: Role of additional carcinoma in situ and background parenchymal enhancement.
Preibsch H; Richter V; Bahrs SD; Hattermann V; Wietek BM; Bier G; Kloth C; Blumenstock G; Hahn M; Staebler A; Nikolaou K; Wiesinger B
Eur J Radiol; 2017 May; 90():181-187. PubMed ID: 28583631
[TBL] [Abstract][Full Text] [Related]
39. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study.
Chen Y; Chen K; Xiao X; Nie Y; Qu S; Gong C; Su F; Song E
BMC Cancer; 2016 May; 16():320. PubMed ID: 27198767
[TBL] [Abstract][Full Text] [Related]
40. Automated rating of background parenchymal enhancement in MRI of extremely dense breasts without compromising the association with breast cancer in the DENSE trial.
Wang H; H M van der Velden B; Verburg E; Bakker MF; Pijnappel RM; Veldhuis WB; van Gils CH; Gilhuijs KGA
Eur J Radiol; 2024 Jun; 175():111442. PubMed ID: 38583349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
